pimobendan Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| cardiac stimulants, pimobendan derivatives | 2171 | 74150-27-9 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
produces arterial & venous dilatation in dogs; structure given in first source
|
Drug dosage:
None
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| Vd (Volume of distribution) | 2 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 14 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.02 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 1.80 hours | Lombardo F, Berellini G, Obach RS |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Jan. 1, 1994 | YEAR INTRODUCED |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Cardiac failure | 162.57 | 42.21 | 51 | 463 | 85793 | 53262759 |
| Renal impairment | 42.25 | 42.21 | 19 | 495 | 83299 | 53265253 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Cardiac failure | 141.40 | 39.17 | 60 | 738 | 91613 | 32421115 |
| Cardiac failure chronic | 51.85 | 39.17 | 15 | 783 | 7225 | 32505503 |
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| MeSH PA | D002316 | Cardiotonic Agents |
| MeSH PA | D002317 | Cardiovascular Agents |
| MeSH PA | D004791 | Enzyme Inhibitors |
| MeSH PA | D010726 | Phosphodiesterase Inhibitors |
| MeSH PA | D020011 | Protective Agents |
| MeSH PA | D014665 | Vasodilator Agents |
| CHEBI has role | CHEBI:35620 | vasodilator |
| CHEBI has role | CHEBI:38147 | cardiotonic drugs |
| CHEBI has role | CHEBI:50218 | phosphodiesterase inhibitors |
Drug Use (View source of the data)
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 10.86 | acidic |
| pKa2 | 11.61 | acidic |
| pKa3 | 4.76 | Basic |
| pKa4 | 4.16 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Phosphodiesterase 3 | Enzyme | INHIBITOR | IC50 | 6.39 | CHEMBL | SCIENTIFIC LITERATURE | |||
| Type-1 angiotensin II receptor | GPCR | IC50 | 4.77 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| D01133 | KEGG_DRUG |
| C0071071 | UMLSCUI |
| CHEBI:32003 | CHEBI |
| CHEMBL24646 | ChEMBL_ID |
| DB11450 | DRUGBANK_ID |
| C041648 | MESH_SUPPLEMENTAL_RECORD_UI |
| 4823 | PUBCHEM_CID |
| 5090 | INN_ID |
| 34AP3BBP9T | UNII |
| 1110783 | RXNORM |
| 017800 | NDDF |
Pharmaceutical products:
None